Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Fox Chase Cancer Center and Temple Health Welcome Urologist Dr. Steve Sterious
PHILADELPHIA (July 21, 2022)—Fox Chase Cancer Center is pleased to announce the hiring of Steve Sterious, MD, FACS, who has joined Temple Health and the Fox Chase Division of Urology and Urologic Oncology.
“Dr. Sterious will be joining an experienced team of benign urologists which will work integrally with the urologic oncology team already well established at Fox Chase. The infusion of expertise that these physicians bring will further help us expand the range of advanced benign urologic treatment options available at Fox Chase and for Temple Health at large,” said Robert Uzzo, MD, MBA, FACS, President & CEO of Fox Chase Cancer Center.
Sterious has been serving patients in the Philadelphia region for more than a decade. He has expertise in a variety of urological conditions, including advanced benign prostatic hyperplasia (BPH), urinary tract infection, erectile dysfunction, kidney stones, and incontinence. His specialties include minimally invasive and robotic surgery, kidney stone surgery, and erectile dysfunction and hypogonadism.
In addition to being named Resident Teacher of the Year by chief residents at Einstein urology in Philadelphia, he was the first physician in Pennsylvania to perform Aquablation, a unique BPH therapy that uses a water jet for removal of tissue.
Sterious earned his medical degree from Jefferson Medical College in Philadelphia and completed his residency training at Temple University Hospital. He served as chief resident of urology there, as well as chief resident of urologic oncology at Fox Chase during his postgraduate training. He went on to work as a urologist for Einstein Medical Center before joining Fox Chase.
“The addition of Dr. Sterious to our urology practice represents an exciting step forward in our clinical offerings for patients with urologic conditions, further distinguishing us as leaders in the field,” said Uzzo.
Sterious began working at Fox Chase on July 1 and will see patients at Fox Chase Cancer Center East Norriton—Hospital Outpatient Center and Temple Health Ft. Washington.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427